CD274 and non-small cell lung carcinoma: In addition, a separate trial studying the role of the microbiome in predicting toxicity of the anti-PD-L1 agent durvalumab following concurrent chemoradiation in locally advanced NSCLC patients is open to accrual (ClinicalTrials.gov Identifier: NCT04680377; PI Dr. Jun Zhang).